Skip to main navigation Skip to search Skip to main content

Preclinical Evaluation of Dual NOP/Mu Partial Agonists for Methamphetamine Use Disorder

  • Thamires Righi
  • , Gilles Zribi
  • , Sebastian Garcia
  • , Stephen M. Husbands
  • , Lawrence Toll
  • , Andrea Cippitelli
  • Charles E. Schmidt College of Medicine
  • Florida Atlantic University

Research output: Contribution to journal › Article › peer-review

Abstract

Background/Objectives: Methamphetamine (meth) use disorder (MUD) continues to pose a significant public health challenge, and there are currently no FDA-approved pharmacological treatments available. Compounds that simultaneously activate nociceptin opioid peptide (NOP) and mu opioid receptors offer a promising therapeutic approach for substance use disorders, including psychostimulant addiction. Methods: We evaluated two mixed NOP/mu receptor agonists for their ability to reduce meth intake using a translational drug-versus-food choice self-administration paradigm in male and female Sprague–Dawley rats. In addition, both compounds were tested in female rats for their effects on cue- and priming-induced reinstatement of meth-seeking behavior, established preclinical models of relapse. Results: PPL-138 and PPL-143 are structurally related bifunctional NOP/mu partial agonists that exhibit greater efficacy at NOP than at mu receptors, with PPL-143 showing the highest NOP efficacy. In behavioral assays, both compounds significantly reduced meth self-administration in male rats and exhibited comparable potency in this effect. In female rats, however, PPL-143 was less effective than PPL-138 in reducing meth intake. In reinstatement models, PPL-138, but not PPL-143, attenuated prime-induced reinstatement of meth seeking, whereas both compounds produced comparable increases in meth seeking in the cue-induced reinstatement paradigm. Additional findings indicated that PPL-138 enhanced meth-induced locomotor activation. Conclusions: The findings support mixed mu/NOP partial agonists as a promising pharmacological strategy for treating MUD, while also indicating a potential for increased drug seeking under certain conditions. Notably, enhancing the NOP component does not appear to meaningfully improve either the safety profile or the anti-meth efficacy of these bifunctional ligands.

Original languageEnglish
Article number1119
Number of pages17
JournalPharmaceuticals
Volume19
Issue number7
Early online date20 Jul 2026
DOIs
Publication statusPublished - 31 Jul 2026

Data Availability Statement

Study data will be provided upon request.

Acknowledgements

We thank the NIDA drug supply program for donating the methamphetamine hydrochloride.

Funding

This research was funded through NIH award 1R41DA057430-01, which was granted to A.C. and L.T.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • choice
  • cues
  • food
  • methamphetamine
  • mu opioid receptor
  • NOP receptor
  • priming
  • reinstatement
  • reward
  • seeking
  • self-administration

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Preclinical Evaluation of Dual NOP/Mu Partial Agonists for Methamphetamine Use Disorder'. Together they form a unique fingerprint.

Cite this